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ABSTRACT
Objective: This paper reveals the studies of carbamazepine monitoring in the manifestation of side effects during clinical use. It is important to 
realize that these ranges are derived statistically, with most patients who have high levels suffering side effects and some with poor control having 
low levels. Broadly, the newer agents have advantages of lower risk of side effects and less drug interaction. At the presence they are more expensive 
than the, than “older” agents. Current recommendations and practice are to use newer agents as second line drugs, although in some countries 
there are gaining favour as potential first line agents. Methods: In the study 91 patients with epilepsy were involved from which 53 or 58.2% 
were female and 38 or 41.8% were male with no great significant difference between two genders (X2=2.47, P=0.116). However, according to 
the study results female patients had slightly greater prevalence of epilepsy than man. Average age of epileptic patients was 23.2 years (SD ± 16.4 
years), in the range 1–66 years. Patient distribution was present within all age-groups, but 59.4% of all patients were up to 20 years old. The high-
est prevalence of epilepsy was in the group age 6-15 years old: 33.0%. There were also children 1 – 5 years old with 7 or 7.7% of the patients, and 
the patients older than 60 years with 4 or 4.4% of the patients. Patient distribution according to the age and gender results with no female patient 
over 60 year old and more female patients in the age group 1-5 years. However statistically this did not produce a highly significant difference 
(T-test= 0.72, P=0.437) between average age according to the gender. The average age of the female gender was 22.1 year (SD ± 14.2 years), with 
the range 2-55 years, while the average age of the male patients was 24.6 year (SD ±19.2 years), with the range 1-66 years. Conclusion: Unwanted 
side effects of antiepileptic drugs analyzed in the study are frequent, but not so severe as to be life threatening. Treatment of epilepsy with these 
three drugs (carbamazepine, ac.valproic and phenobarbitone) would be the first choice of treatment, with the best safety and efficacy. Application 
of this therapy is rarely compromised because of the appearance of unwanted side effects. Replacement or termination of therapy may be applied 
if actual therapy is not adequate for the management of epileptic attacks.
Key words: Carbamazepine, antiepileptics, side effects.
1. INTRODUCTION
Epilepsy is one of the most common neurologic problems 
worldwide. It is also the second most common chronic neuro-
logical condition seen by neurologists (1). In recent years, im-
portant advances have been made in the diagnosis and treatment 
of seizure disorders (2).
Epilepsy syndrome can be also classified according to the type 
of seizure, the presence or absence of neurologic or developmen-
tal abnormalities and electroencephalographic (EEG) findings 
(3). For example, the syndrome of juvenile myoclonic epilepsy 
is characterized by the onset of myoclonic seizures, generalized 
tonic-clonic seizures, and less frequently absence seizures in 
adolescents who have normal intellectual function, with EEG 
findings of rapid, generalized spike-wave and polyspike-wave 
discharges (4). In epilepsy, a common problem is diagnostic 
accuracy as it can be diagnose only by taking a history of the 
index event or by chance observation of a seizure (5). As many 
as 10%-20% of cases referred to specialized epilepsy units with 
seemingly intractable seizures do not have epilepsy (6). Up to 
30% of patients developing epilepsy will eventually be classified 
as having chronic epilepsy (7).
The commonest method of case ascertainment is a retrospec-
tive review of medical notes, for seizures, antiepileptic drugs, 
EEG or a diagnostic coding (8).
Congenital, developmental, and genetic conditions are as-
sociated with epilepsy in childhood, adolescence, and in young 
adults. In elderly people cerebrovascular disease is common. 
Head trauma, sporadic CNS infection, and tumors may occur 
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at any age although tumors are more likely over the age of 40. 
Few study found in addition that had injury, developmental de-
lay, and a family history of epilepsy were significant risk factors.
Further investigations (EEG/CT-MRI as appropriate) 
should be done in evaluation of a suspected epileptic seizure 
(defined on basis of a careful history) to aid diagnosis, classifi-
cation and prognosis (9).
Electroencephalography (EEG) is often helpful in the di-
agnosis and classification of epilepsy. Nonspecific EEG abnor-
malities are relatively common, especially in the elderly, patients 
with migraine, psychotic illness and psychotropic medication. 
Non-specific abnormalities should not be interpreted as sup-
porting a diagnosis of epilepsy (10).
Magnetic Resonance Imaging (MRI) scanning is the cur-
rent standard of reference in the investigation of patients with 
epilepsy. Routine MRI brain scanning using simple standard 
sequences will detect lesions (e.g. Small tumors, vascular mal-
formations ) that are not detected by computed tomography 
(CT) (11).
CT scanning has a role in the urgent assessment of seizures, 
or when MRI is contraindicated (e.g. when patients have pace-
makers or metallic implants) (12).
This paper provides an estimation of the prevalence of epi-
lepsy in the population in Kosovo and prevalence of side effects 
from the different antiepileptic drugs used for the treatment. 
Objectives of study are: 1. Prevalence of epilepsy (vs type of 
epilepsy, gender and age); 2.Types of Treatment (monotherapy/
polytherapy) vs types of epilepsy, and 3. Side effects of antiepi-
leptic drugs (carbamazepine) in patients with different types 
of epilepsy.
2. METHODS
In this study specialistic reports, and the histories of 294 of 
patients with epilepsy that have been treated with antiepileptic 
drugs have been analyzed and evaluated.
In my study were involved 91 (30,95%) from these patients, 
with identified side effects during the treatment with antiepi-
leptic drugs: carbamazepine, ac.valproic and phenobarbitone.
For this study I have analyzed these parameters: age, gender, 
the history of illness, life anamnesis, electroencephalogram 
results, side effects of the drugs, duration of seizures, and fre-
quency of seizures.
This study is based in pharmaco-epidemiology analyzes, ret-
rospective-prospective study, by using the comparative method 
of side effects of carbamazepine, ac.valproic and phenobarbitone 
during the treatment of epilepsy ( Primary Generalized Epilepsy, 
Secondary Generalized Epilepsy, Partial Epilepsy) in Neurol-
ogy Clinic in University Clinical Center of Kosova (UCCK).
The pharmaceutical form of the AED (used by the patients) 
in this study is tablet.
Based on the diagnose of epilepsy, in study are included:
 ■ 37 patients with Primary Generalized Epilepsy,
 ■ 12 patients with Partial Epilepsy,
 ■ 46 patients with Second Generalized Epilepsy,
 ■ EEG has been done to all of 294 patients.
Statistical processing
Data presentation is done through tables and graphs.
From statistical parameters were calculated structure index, 
the arithmetic average, standard deviation and minimum and 
maximum values.
It is used the One Way ANOVA Test which is a compilation 
of statistical models and their common procedures, in which 
the observed changes, in particular variables broken down into 
components of different sources of this variation.
ANOVA is a statistical test used to compare many groups, 
and it replaces t-test. ANOVA is used when more than two 
groups have to be evaluated. The use of t-test for this purpose 
would lead to potential errors, which are avoided when ANOVA 
as statistical method is used.
Questionnaire composed of six units contained the following 
information (variables), which were studied and were statisti-
cally evaluated. These six units are:
 ■ General information: name, surname, age, gender, birth-
place, residence, diagnosis,
 ■ Etiology (causes) of epilepsy: what the patients suspected 
the cause of epilepsy was: high fever, hereditary, CNS 
infections or trauma,
 ■ Diagnose, what type of epilepsy the patients have: Pri-
mary Generalized Epilepsy, Partial Epilepsy, or Secondary 
Generalized Epilepsy,
 ■ Therapy, is it monotherapy or polytherapy with drugs: 
carbamazepine, ac.valproic, phenobarbitone,
 ■ Side effects of antiepileptic drug (carbamazepine, 
ac.valproic, phenobarbitone).
3. RESULTS
In the study 91 patients with epilepsy were involved from 
which 53 or 58.2% were female and 38 or 41.8% were male with 
no great significant difference between two genders (X2=2.47, 
P=0.116).
Distribution of patients according to the age and types of 
epilepsy resulted with statistically high significant difference 
(F-test= 10.58, P=0.0001) between average age according to 
types of epilepsy.
Lower average age of patients with Primary General Epilepsy 
was 16.9 years (SD ± 7.4 years), and the range of 8-36 years, 
Age
Gender
Total
Female Male
N % N % N %
1-5 year 5 9.4 2 5.3 7 7.7
6-15 year 16 30.2 14 36.8 30 33.0
16-20 year 9 17.0 8 21.1 17 18.7
21-40 year 16 30.2 6 15.8 22 24.2
 41-60 year 7 13.2 4 10.5 11 12.1
>60 year - - 4 10.5 4 4.4
Total N 53 100.0 38 100.0 91 100.0
 % 58.2 - 41.8 - 100.0 -
Table 1. Prevalence of epilepsy vs gender and age
Parameters
Gender
Total
Female Male
N 53 38 91
Mean 22.1 24.6 23.2
SD 14.2 19.2 16.4
Min 2 1 1
Max 55 66 66
T-test T=0.72  
P-value P=0.473  
Table 2. Age vs gender parameters
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followed by Secondary Generilazed Epilepsy: 24.0 years (SD ± 
18.3 years), with range of 1-66 years, wile highest average age 
of the patients was with Partial Epilepsy: 39.5 years (SD ±18.5 
years), with range of 17-65 years ( Table 3).
Analysis of the treatment according to the type of epilepsy, 
nearly two thirds: 72 or 79.1% of the patients were treated with 
monotherapy wile 19 or 20.9% of the patients were treated with 
polytherapy.
According to the epilepsy types, nearly half of the patients 
treated with monotherapy: 34 or 47.2% were with Primary 
Generalized Epilepsy, followed with 28 or 38.9% with Sec-
ondary Generalized Epilepsy and only 10 or 13.9% were with 
Partial Epilepsy.
In 19 patients treated with polytherapy, most of them: 14 or 
73,3% were with Secondary Generalized Epilepsy, followed by 
Primary Generalized Epilepsy with 3 patients or 15.8% and 2 
patients or 10.5% with Partial Epilepsy (Table 4).
Analysis of types of epilepsy according to the age group is 
analyzed in 53 patients or 58.2% female and 38 patients or 
41.8% male patients. The lowest number of patients resulted 
with Partial Epilepsy with 12 or 13.2%, followed by Primary 
Generalized Epilepsy with 37 patients or 40.7% and most of 
the patients were with Secondary Generalized Epilepsy with 42 
patients or 46.2%. The lowest number of cases within female 
group are with Partial Epilepsy resulting in 8 patients or 15.1%, 
and Primary Generalized Epilepsy and Secondary Generalized 
Epilepsy were 23 cases 43.4% and Sec Gen Ep with 22 cases 
41.5% respectively. In the male group of patients there is also 
a similar result as in the female group: lowest number is with 
Partial Epilepsy with 4 cases or 10.5%, followed by Primary 
Generalized Epilepsy with 14 cases or 36.8% and most of the 
patients were with Secondary Generalized Epilepsy with 20 
patients or 52.6%. (Table 5).
Secondary Epilepsy Group is present in all age groups. The 
highest number of cases with secondary generalized epilepsy 
was present in the age groups 6-15 years and 21-40 years with 
11 cases each or 26.2%, in age groups 1-5 years and 41-60 years 
with 7 cases each or 16.7%, the incidence below 10% resulted 
in group ages 16-20 years with 4 patients or 9.5% and >60 years 
with 2 cases or 4.8% .
Analysis of distribution of epilepsy cases within the age 
groups resulted with no Primary Generalized Epilepsy in the 
age group 1-5 years and over 41 years old, and more than half 
of the patients with this type of epilepsy were within the age 
group 6-15 years with 19 cases or 51.4%. Other age groups were 
represented with 10 cases or 27.0% in the age group of 16-20 
years and with 8 cases or 21.6% in the age group of 21-40 years.
The Partial epilepsy type was not present up to the age of 15 
Age groups 16-20 years and 21-40 years resulted in 3 patients 
in each group, or 25.0%. 4 cases or 33.3% were in the age group 
41-60 years, and the lowest number of cases resulted in patients 
older than 60 years with only 2 patients or 16.7%. (Table 6).
The patients were treated in 64 cases or 70.3% with Carbam-
azepine, in 19 cases or 20.9% with Valproic acid and in 8 cases 
or 8.8% with Phenobarbitone. Carbamazepine 28 patients or 
43.8% were with Secondary Generalized Epilepsy, 25 patients 
or 39.1% with Primary Generalized Epilepsy and 11 patients or 
17.2% with Partial Epilepsy.(Table 7).
Types of epilepsy were analyzed also according to the cause. 
Almost half of the causes were Trauma with 43 cases or 47.3%, 
high fever in 28 cases or 30.8%, Central nervous system infec-
tions in 12 cases or 13.2% and hereditary causes resulted in 
lowest number of the cases with 8 patients or 8.8%.
In the patient group with Trauma as a cause we had 22 cases 
or 51.2% with primary generalized epilepsy, 17 cases or 39.5% 
with secondary generalized epilepsy and 4 cases or 9.3% with 
partial epilepsy. In the patient group with high fever as a cause 
Type of epilepsy
Treatment type
Total
Monotherapy Polytherapy
N % N % N %
Prim Gen Ep 34 47.2 3 15.8 37 40.7
Partial Ep 10 13.9 2 10.5 12 13.2
Sec Gen Ep 28 38.9 14 73.7 42 46.2
Total N 72 100.0 19 100.0 91 100.0
 % 79.1 - 20.9 - 100.0 -
Table 4. Treatment vs type of epilepsy
Type of epilepsy
Gender
Total
Female Male
N % N % N %
Prim Gen Ep 23 43.4 14 36.8 37 40.7
Partial Ep 8 15.1 4 10.5 12 13.2
Sec Gen Ep 22 41.5 20 52.6 42 46.2
Total N 53 100.0 38 100.0 91 100.0
 % 58.2 - 41.8 - 100.0 -
Table 5. Types of epilepsy vs gender
Age
Type of Epilesy
Total
Prim Gen Ep Partial Ep Sec Gen Ep
N % N %     N %
1-5 year - - - - 7 16.7 7 7.7
6-15 year 19 51.4 - - 11 26.2 30 33.0
16-20 year 10 27.0 3 25.0 4 9.5 17 18.7
21-40 year 8 21.6 3 25.0 11 26.2 22 24.2
 41-60 year - - 4 33.3 7 16.7 11 12.1
>60 year - - 2 16.7 2 4.8 4 4.4
Total N 37 100.0 12 100.0 42 100.0 91 100.0
 % 40.7 - 13.2 - 46.2 - 100.0 -
Table 6. Type of epilepsy vs ages
Type of epi-
lepsy
Antiepileptic drug
Total
Carbamazepine Ac. Valproic Phenobar-biton
N % N % N % N %
Prim Gen Ep 25 39.1 8 42.1 4 50.0 37 40.7
Partial Ep 11 17.2 - - 1 12.5 12 13.2
Sec Gen Ep 28 43.8 11 57.9 3 37.5 42 46.2
Total N 64 100.0 19 100.0 8 100.0 91 100.0
 % 70.3 - 20.9 - 8.8 - 100.0 -
Table 7. Treatment vs disease
Type of 
epilepsy
Causes
Total
High fever Hereditary CNS infec-tions Trauma
N % N % N % N % N %
Prim Gen Ep 11 39.3 4 50.0 - - 22 51.2 37 40.7
Partial Ep 2 7.1 - - 6 50.0 4 9.3 12 13.2
Sec Gen Ep 15 53.6 4 50.0 6 50.0 17 39.5 42 46.2
Total N 28 100.0 8 100.0 12 100.0 43 100.0 91 100.0
 % 30.8 - 8.8 - 13.2 - 47.3 - 100.0 -
Table 8. Type of epilepsy vs cause
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there were: 15 cases or 53.6% with Secondary Generalized 
Epilepsy, 11 patients or 39.3% with primary generalized epi-
lepsy, and 2 patients or 7.1% with partal epilepsy. In the group 
with Central Nervous System Infection as a cause there were 6 
patients or 50% with Partial Epilepsy and 6 or 50% with Sec-
ondary Generalized Epilepsy, and in the group of Hereditary 
causes there were 4 patients or 50% with Primary Generalized 
Epilepsy and also 4 patients or 50% with Secondary General-
ized Epilepsy (Table 8).
In patients involved in the study regardless of the type of 
treatment the most common side effects reported were Drowsi-
ness and Dizziness with 23 cases or 25.3% of all patients (n=91), 
Nausea with 19 cases or 20.9%, Tiredness and Weight gain with 
14 cases or 15.4%, Skin rash and Trouble sleeping with 8 cases 
or 8.8% and Tremor with 3 cases or 3.3%.
The distribution of side effects according to the antiepileptic 
treatment resulted in difference with high statistical signifi-
cance. ( KW=10.50, P=0.0052).
Most common side effects of Carbamazepine in all types of 
epilepsy were : Dizziness with 20 cases or 31.3%, Nausea and 
Drowsiness with 17 cases or 26.6% each , Weight gain with 11 
cases or 17.2%, Tiredness with 6 cases or 9.4%, Trouble sleeping 
with 5 cases or 7.8%, Skin rash with 4 cases or 6.3% and Tremor 
with 3 cases or 4.7%. In our study, in the patients treated with 
Carbamazepine, no side effect of vomiting was reported.
Analysis of side effects of Carbamazepine in types of epilepsy 
showed that vomiting was not reported in any of the types of 
epilepsy, in Primary Generalized Epilepsy Tiredness was not 
reported and at Partial epilepsy nausea, tremor nor skin rash 
were not reported as side effects.
Most common side effects of Carbamazepine in Primary 
Generalized Epilepsy were drowsiness and dizziness with 9 
cases or 36.0% each, nausea with 8 cases or 32.0%, tremor and 
weight gain with 2 cases or 8.0% each and trouble sleeping and 
skin rash with 1 case or 4.0% each. Most common side effects 
of Carbamazepine in partial epilepsy were drowsiness with 5 
cases or 45.5%, weight gain with 4 cases or 36.4%, tiredness and 
dizziness with 3 cases or 27.3% and 1 case or 9.1% with trouble 
sleeping. Most common side effects of Carbamazepine in Sec-
ondary Generalized Epilepsy were: nausea 9 cases or 32.1%, diz-
ziness with 8 cases or 28.6%, weight gain with 5 cases or 17.9%, 
drowsiness, trouble sleeping, tiredness and skin rash with 3 cases 
or 10.7% each, and tremor 1 case or 3.6%.
4. DISCUSSION
To ensure a maximal effectivity of the treatment and minimal 
side effects, a coordination between the treatment, patient and 
doctor should be established.
Currently in market there are many new antiepileptic drugs, 
but still as first line antiepileptic treatment remain carbamaze-
pine, valproic acid and phenobarbitone. This doesn’t mean that 
other antiepileptic drugs, especially Lamotrigine, is not in use, 
but this is more as a second line treatment.
According to the study results female patients had greater 
prevalence of epilepsy than man. The highest prevalence of 
epilepsy was in the group age 6-15 years old: 33.0%.
The average age of female patients was 22.1 years compared 
with male patients was 24.6 years, so with the t-test the average 
difference is not considered significant.
The average age of disease vs types of epilepsy has resulted 
in significant difference, with the highest average age (39.5) in 
Partial Epilepsy, and with the lowest in Primary Generalized 
Epilepsy (16.9).
With the classification of the patients by age group and gen-
der, the difference is significant. In patients aged 21-40 years 
the prevalence of women vs. men is higher (30.2% vs. 15.8%), 
whereas in the patients aged 6-15 years the prevalence is higher 
among males. (F 30.2% vs. M 36.8%).
The prevalence of epilepsy was higher in females 30.2% (in 
age group 21-40 years) compared with men 15.8%, and this may 
be due to the increased exposure of adult female toward trauma 
during the war in our country, due to socioeconomic factors, our 
mentality, and also predisposition of females against epilepsy.
In patients over 60 year old the number of men affected 
by epilepsy in our study is higher, as a result of possible infec-
tions in CNS, tumors, without ignoring the influence of the 
hazardous working environment. In our country, males are 
predominantly engaged in working places with hazardous and 
stressful environment.
About 50 million people worldwide have epilepsy, with most 
90% of these people being in developing countries(13). Epilepsy 
is more likely to occur in young children or people over the age 
of 65 year; however it can occur at any time. As consequence 
of brain surgery epileptic seizures may occur in recovering 
patients. Epilepsy is usually controlled, but cannot be cured 
with medication, although surgery may be considered in dif-
ficult cases. However 30% of people with epilepsy do not have 
seizure control even with the best available medications. Not 
all epilepsy syndromes are lifelong, some forms are confined to 
particular stages of childhood. Epilepsy should not understand 
Side effects
Antiepileptic drug
Total
K
ru
sk
al
 
W
al
lis
 te
sti
Carbama-
zepine
Ac. 
Valproic
Phenoba-
rbiton
N % N % N % N %
TOTAL 64 100.0 19 100.0 8 100.0 91 100.0
K
W
=1
0.
50
P=
0.
00
52
Nausea 17 26.6 1 5.3 1 12.5 19 20.9
Drowsiness 17 26.6 5 26.3 1 12.5 23 25.3
Dizzines 20 31.3 3 15.8 - - 23 25.3
Tiredenes 6 9.4 6 31.6 2 25.0 14 15.4
Vomiting - - 4 21.1 3 37.5 7 7.7
Troub sleep 5 7.8 1 5.3 2 25.0 8 8.8
Tremor 3 4.7 - - - - 3 3.3
Weight gain 11 17.2 3 15.8 - - 14 15.4
Skin rash 4 6.3 2 10.5 2 25.0 8 8.8
Table 9. Side effects vs treatment
Side effects 
Carbamazepine
Type of epilepsy
Prim Gen Ep Partial Ep Sec Gen Ep
N % N % N %
TOTAL 25 100.0 11 100.0 28 100.0
Nausea 8 32.0 - - 9 32.1
Drowsiness 9 36.0 5 45.5 3 10.7
Dizziness 9 36.0 3 27.3 8 28.6
Tiredness - - 3 27.3 3 10.7
Vomiting - - - - - -
Troub sleep 1 4.0 1 9.1 3 10.7
Tremor 2 8.0 - - 1 3.6
Weight gain 2 8.0 4 36.4 5 17.9
Skin rash 1 4.0 - - 3 10.7
Table 10. Side effects of Carbamazepine vs type of epilepsy
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as a single disorder, but rather as syndromes with vastly diver-
gent symptoms but all involving episodic abnormal electrical 
activity in the brain (14).
From hospital and clinic studies it is well known that the 
range of etiologies in the epilepsies varies in different age groups 
and also according to geographic location. Approximately 75% 
of all cases of epilepsy have no known causes. This is referred to 
as idiopathic epilepsy. The other 25% of cases have known the 
etiology (15). In the United Kingdom National General Prac-
titioners study of epilepsy, seizures were classified as idiopathic 
in 72%, remote symptomatic in 25%, and the remaining 3% 
were associated with neurological deficits present at birth (16).
Most reports show slightly higher rates in males than in 
females. This is because the females consult their general practi-
tioner for episodes of disturbed consciousness of any sort twice 
as often as males (17). There are also several small scale reports 
showing high rates in black population. A lower standard of 
perinatal care might be relevant and socioeconomic factor (5).
Incidental epileptiform abnormalities are found in 0.5% of 
healthy young adults, but are more likely in people with learn-
ing disability and psychiatric disorders, patients with previous 
neurological insult (e.g. meningitis, stroke, cerebral palsy) and 
patients who have undergone neurosurgery (18). The finding of 
epileptiform abnormalities is specific and the diagnostic value 
of the test is good. In a patient in whom the history is typical of 
some other disorder, the prevalence of epilepsy will be low, and 
any epileptiform abnormalities are more likely to be incidental, 
the test should not be performed in this circumstances (19).
It is worth mentioning that as accurate as diagnosis can be 
the possibility of the appearance of side effects is less possible.
5. CONCLUSION
 ■ Based on the analysis of results of the study, literature 
review and publications I may consider that:
 ■ Unwanted side effects of antiepileptic drugs analyzed 
in the study are frequent, but not so severe as to be life 
threatening. Treatment of epilepsy with these three drugs 
(carbamazepine) would be the first choice of treatment, 
with the best safety and efficacy. Application of this 
therapy is rarely compromised because of the appearance 
of unwanted side effects. Replacement or termination of 
therapy may be applied if actual therapy is not adequate 
for the management of epileptic attacks.
 ■ In general, therapy with these three antiepileptic drugs 
is well tolerated by the organism, and most patients feel 
better as a result of this therapy, which was evidenced by 
the results of good management of epileptic attacks in 
our study patients.
 ■ The greatest number of patients reported Trauma as the 
cause of epilepsy with 43 cases or 47.3%. Hereditary 
causes resulted in lowest number of the cases with 8 pa-
tients or 8.8%.
 ■ Epilepsy should be treated continuously, by carefully 
choosing appropriate therapy. In particular, it is im-
portant to ensure a proper approach in management of 
epilepsy always considering life quality and life length of 
the patients.
 ■ As we know the epilepsy cannot be cured, but it can be 
managed with a careful choice of an effective treatment 
and dosage.
 ■ We hereby declare: that the manuscript is original and 
the work has not been published elsewhere.
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